Showing 4841-4850 of 6660 results for "".
- New Option for Molluscum Expected Soonhttps://practicaldermatology.com/news/New-Option-Molluscum-Expected-Soon/2471226/Perhaps the most important measure a dermatologist can take after diagnosing a patient with molluscum is to reassure them that it is not a big deal, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at Winter Clinical Hawaii 2025 in Waikoloa Village, Hawaii.
- Care Urged for Adult-Onset AD Diagnoseshttps://practicaldermatology.com/news/Care-Urged-Adult-Onset-AD-Diagnoses/2471216/As revolutionary as the latest approved therapeutics for atopic dermatitis have been, Daniela Kroshinsky, MD, MPH, cautioned that dermatologists must be vigilant and consider biopsies for atypical or nonresponsive cases before starting dupilumab or a JAK inhibitor. Speaking at the Winter C
- 'Dr. Pimple Popper' Offers Social Media Advicehttps://practicaldermatology.com/news/Dr-Pimple-Popper-Offers-Social-Media-Advice/2471209/Social media transformed Sandra Lee, MD, FAAD, FAACS, into “Dr. Pimple Popper.” While not every dermatologist aspires to have their own television show, many would like to maximize the impact of their social media presence, and Dr. Lee shared pearls from her own experience at the Winter Clinical
- Dr. Swanson: Dupilumab/Vaccines Question Has Been Answeredhttps://practicaldermatology.com/news/Dr-Swanson-Dupilumab-Vaccines-Question-Has-Been-Answered/2471166/The biggest remaining question about dupilumab has been answered by the allergy and immunology community, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “The only realy question
- Acne Vaccine Could Be 'Revolutionary,' Dr. Stein Gold Sayshttps://practicaldermatology.com/news/Acne-Vaccine-Could-Be-Revolutionary-Dr-Stein-Gold-Says/2471165/The next major breakthrough in acne could be a “revolutionary” vaccine targeting the strain of c. Acnes bacteria that produces the Hyl-A enzyme, Linda Stein Gold, MD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “It is still in early clinical trials, but I t
- Guselkumab Effective in Psoriasis Regardless of Prior Treatment History: Studyhttps://practicaldermatology.com/news/guselkumab-effective-regardless-of-prior-treatment-history-study/2471126/Guselkumab was effective at managing moderate-to-severe psoriasis over five years, regardless of baseline disease severity or treatment history, according to a post hoc analysis of the VOYAGE 1 and 2 trials. The study looked
- New Dupilumab Data for CSU to Be Presented at AAAAI Meetinghttps://practicaldermatology.com/news/New-Dupilumab-Data-CSU-Be-Presented-AAAAI-Meeting/2471105/New phase 3 data on dupilumab for chronic spontaneous urticaria (CSU) will be among 24 abstracts presented by Sanofi at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, California, from February 28 to March 3. The dupilumab CSU data from the LIBER
- Football Star OBJ to Raise Awareness of Seborrheic Dermatitis With Arcutishttps://practicaldermatology.com/news/Football-Star-OBJ-Raise-Awareness-Seborrheic-Dermatitis-With-Arcutis/2471099/NFL star Odell Beckham Jr. will help raise awareness of seborrheic dermatitis as part of a partnership with Arcutis Biotherapeutics, the company announced. “Seb derm is such a common condition, but like me, many people may have a hard time trying to figure out what it is and what can be do
- Pacific Northwest Practice Hiringhttps://practicaldermatology.com/news/Pacific-Northwest-Practice-Hiring/2471098/Clear Choice Dermatology announced it is seeking a board-certified dermatologist to work in its locations in Portland, Oregon, or Salem, Oregon. Clear Choice has 11 locations throughout Oregon and Washington. Owner and Chief Medical Officer Collin Blattner, DO, FAAD, is a member of Pra
- Phase 1 Study Begins for New Systemic for CPUOhttps://practicaldermatology.com/news/Phase-1-Study-Begins-New-Systemic-CPUO/2471095/The first subject has been dosed in a first-in-human Phase 1 study of ATTO-1310, a novel, subcutaneous (SQ), half-life extended (HLE) anti-IL-31 biotherapeutic, Attovia Therapeutics announced. ATTO-1310 is being evaluated as a potential systemic treatment for people living with pruritic co